PDCD1LG2 and neoplasm: The ligands PD-L1 and PD-L2 are then upregulated in tumor, stromal, and immune infiltrate cells, and these ligands interact with PD-1 on tumor-infiltrating T cells, causing a decrease in their cytotoxic response [78, 79].